AHH to Acquire Majority Stake in Dr Dangs Labs

The acquisition comes amid a significant influx of foreign direct investment (FDI) into India’s healthcare sector.

GIC- backed Asia Healthcare Holdings (AHH) has announced that it is going to acquire a majority stake in Delhi-based Dr Dangs Labs.

The deal is the latest in a series of high-profile investments that underscore the rising global interest in India’s healthcare sector. The financial details have not been disclosed yet.

The acquisition aims to expand its infrastructure, adopt digital health technologies, and improve access in Tier 2 and Tier 3 cities.

Further, known for its quality-driven diagnostics, the lab will join AHH’s growing portfolio of single-specialty healthcare enterprises, which includes Motherhood Hospitals, Nova IVF, and the Asian Institute of Nephrology & Urology.

The acquisition comes amid a significant influx of foreign direct investment (FDI) into India’s healthcare sector.

Additionally, global investors such as GIC, TPG, KKR, Temasek, and BPEA EQT are increasingly betting on diagnostics and specialty care as key growth drivers.

Dr Dangs Labs has earned a strong reputation for patient-centric care and advanced pathology services, particularly in Delhi and Gurugram.

Stay tuned for more such updates on Digital Health News.